Introduction
There are numerous disease states that can induce muscle dysfunction, including cardiac disease, diabetes, and various kinds of muscular dystrophy (including Duchenne type). In addition, muscle atrophy and weakness can occur with aging or disuse. Muscle injury can also occur with sports or other activities. Appropriate and sufficient exercise of the muscles does not always provide good recovery. In some circumstances, long periods of time are required to recover muscle function after injury or treatment. Accordingly, the development of clinical interventions to enhance muscle regeneration and to facilitate muscle healing after injury is a very important issue in musculo-skeletal disease research.
Gene transfer is an approach with promising potential in the treatment of many clinical disorders. Various means to achieve gene transfer, including viral, physical, and chemical methods, are currently being explored. There is a need to develop and investigate novel gene transfer methods to improve muscle regeneration and accelerate muscle healing after injury or treatment. Direct gene therapy using retrovirus, adenovirus, herpes simplex virus type I, and adeno-associated viral vectors has achieved successful transduction in vitro and in vivo studies. However, delivery vectors that employ viruses are potentially dangerous due to viral infection-associated toxicity, immunologic compromise, and possible mutagenic or carcinogenic effects. Direct needle injection of naked DNA and plasmid DNA without a viral vector can be used to induce low levels of local expression of an exogenous gene in vitro; 1 However, although such approaches appear to be safe, they are inefficient methods of gene transfer. Electroporation 2, 3 has been used in vivo to introduce DNA into various kinds of cells in order to increase gene delivery and to permit the introduction of large plasmids. Aihara and Miyazaki 4 reported that gene delivery with electroporation could be effectively used in muscle tissue.
Many growth factors have the ability to stimulate and accelerate healing and growth in muscle tissue. 5, 6 Insulin-like growth factor-I (IGF-I) is well known to be an anabolic factor in mediating the growth of muscle, peripheral nerve, and other tissues. IGF-I is an important autocrine/paracrine mediator of skeletal muscle growth and development. IGF-I initially promotes proliferation by enhancing the expression of intracellular mediators such as cyclin D, c-fos, and by suppressing the mediators of myogenin. 7 Overexpression of IGF-I has been correlated with muscle hypertrophy in transgenic mouse lines.
In this study, we hypothesized that IGF-I gene delivery via electroporation would promote repair of muscle injury and, therefore, may be of therapeutic value for the treatment of muscle damage as a result of sports injury or muscle diseases such as muscular dystrophy and muscle ischemia due to arteriosclerosis obliterans. In order to examine the efficiency of the electroporation method for gene transfer of IGF-I DNA, we compared IGF-I DNA injection into the injured muscle with green fluorescent protein (GFP) DNA injection with respect to histological analysis, IGF-I concentration, and electromyographic examination.
Results

Histological evaluation
Muscle fibers were observed by fluorescence microscopy 1 week after injection of GFP DNA (Figure 1 ). Figure 2 shows treated sections from tissue harvested 1, 2, and 4 weeks after injection. The hematoxylin-eosin-stained sections showed that centronucleated myofibers, which are a distinct characteristic of regenerating muscle, were present in the IGF-I DNA-injected group at 1 week after injection (Figure 2a) . However, both IGF-I-and GFP DNA-injected groups (Figure 2b ) showed an infiltration of inflammatory cells. Infiltration of lymphocytes in the Figure 1 Expression of GFP in a cross-section of injury-sutured hamstring muscle at 1 week after injection of GFP DNA. Immediately after injection of the DNA, the muscle was electrostimulated three times with a pulse of 100 V, each pulse being 50 ms in duration followed by three more pulses of opposite polarity. Sections 8-mm in thickness were evaluated with a confocal laser microscope. Figure 2 Representative histological sections of injury-sutured hamstring muscles stained by the H-E method, and taken 1 week after injection and electroporation of (a) IGF-I DNA injection group, (b) GFP DNA injection group, and (c) injury-sutured group (control); 2 weeks after injection and electroporation of (d) IGF-I DNA injection group, (e) GFP DNA injection group, and (f) injury-sutured group (control); and 4 weeks after injection and electroporation of (g) IGF-I DNA injection group, (h) GFP DNA injection group, and (i) injury-sutured group (control). Sham operations were performed in which the muscle was exposed, cut, and sutured alone (control group).
IGF-I gene transfer and muscle regeneration T Takahashi et al GFP-injected group was greater than in the IGF-I-injected and the control groups at 1 and 2 weeks. The same degree of scar tissue formation with inflammatory cell infiltration was observed in the IGF-I-injected group and uninjected injury model (control group) (Figure 2c ), and atrophy surrounding muscle cells were seen at 1 week after injection (2 weeks after injury). In the IGF-I DNA group (Figure 2d ), a decrease in inflammatory cell infiltration and in scar tissue formation was observed after 2 weeks as compared to the GFP DNA group (Figure 2e) . However, at 4 weeks after injection, there was no difference in the degree of infiltration of lymphocytes between IGF-I- (Figure 2g ) and GFPinjected groups (Figure 2h ). After 4 weeks, IGF-I DNAinjected animals ( Figure 2g ) displayed a more pronounced muscle hypertrophy and fewer centronucleated myofibers than at 2 weeks post-IGF-I injection ( Figure  2d ).
The vimentin staining revealed moderate fibrosis (fibroblastic scar tissue) in the IGF-I (Figure 3a With azan staining, the collagen fibers in the IGF-I (Figure 4a ) and the GFP (Figure 4b ) injected groups at 1 week after injection were increased as compared with the control (Figure 4c ). However, at 2 weeks after injection, the collagen fibers in the IGF-I (Figure 4d ) and the control (Figure 4f ) groups decreased similarly, whereas in the GFP group ( Figure 4e ) the decrease was less pronounced. At 4 weeks after injection, some collagen fiber still remained between muscle cells in the GFP group (Figure 4h ). In the IGF-I group (Figure 4g) , however, the collagen fibers were slightly increased and they were more abundant than at 2 weeks after injection.
The mean number of regenerating muscle fibers in the IGF-I DNA-injected group was statistically higher than that in the GFP DNA and control groups 2 weeks after injection, however, the difference was not significant at 1 week after injection. At 4 weeks after injection, that in the IGF-I DNA group was higher than that in the control group (Figure 5a ). No significant difference was observed between the IGF-I DNA and GFP DNA groups with respect to the mean lesser diameter of regenerating muscle fibers at 1 and 2 weeks after injection. However, the mean lesser diameter of the IGF-I DNA injection group was larger than that of the GFP DNA injection at 4 weeks after injection (Figure 5b ).
IGF-I concentration
There was no significant difference between the IGF-I DNA and GFP DNA groups in the serum IGF-I concentration at 1, 2, and 4 weeks after injection ( Figure  6a ). However, muscle IGF-I concentration in the IGF-I DNA injection group was significantly greater than in Figure 3 Representative immunohistochemical sections of injury-sutured hamstring muscles stained by the vimentin method, and taken 1 week after injection and electroporation of (a) IGF-I DNA injection group, (b) GFP DNA injection group, and (c) injury-sutured group (control); 2 weeks after injection and electroporation of (d) IGF-I DNA injection group, (e) GFP DNA injection group, and (f) injury-sutured group (control); and 4 weeks after injection and electroporation of (g) IGF-I DNA injection group, (h) GFP DNA injection group, and (i) injury-sutured group (control).
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Electromyographic analysis
The compound muscle action potentials (CMAP) value in the IGF-I-injected group (mean 10.22 mV) was not significantly higher than in the GFP-injected group (7.93 mV) using Mann-Whitney's U test (P¼0.16), and there was no significant difference between CMAP in the control uninjected group and in the IGF-I uninjected group (P¼0.17). There was an individual variation in the response to the electrical stimulation. Then, we evaluated the CMAP ratio of the injected to the uninjected (intact contralateral) leg and compared the values among the three groups. The CMAP amplitude ratio of the injected versus uninjected sites in the IGF-I DNA injection group was significantly greater than that of the GFP DNA group at 4 weeks after injection and of the control group ( Figure 7 ).
Discussion
There are many methods available to achieve gene transfer into muscle tissue. It has been shown that infection rates using virus vectors are high; however, their safety has not been conclusively demonstrated. In addition, infection with viruses can induce a neutralizing antibody response that reduces the concentration of the recombinant virus. In contrast, plasmid vectors are easier to construct and prepare, and do not introduce a significant risk of contamination by wild-type infectious particles. Electroporation has been found to be an efficient method to transfer genes into human hematopoietic stem cells, and does not involve many of the disadvantages associated with other methods of gene transfer. 8 Gene transfer by electroporation has been used successfully for introduction into mouse skin, 9 liver, brain, and muscle tissue. 4 Muscle electropermeabilization can also provide a safe, affordable, and effective treatment for many diseases by producing therapeutic proteins with systemic effects. 10 . IGF-I is required for cells to traverse the G1 phase of the cell cycle, and is thus referred to as a progressive factor. Mononucleated satellite cells are the myogenic cells responsible for muscle regeneration. These cells are located between the basal lamina and plasma membrane of the muscle fiber. 11 It is known that IGF-I activates satellite cells in vitro, increasing their rate of cellular proliferation and the formation of myotubes. 12 Increases in IGF-I expression are associated with increases in muscle mass. 13 IGF-I-deficient mice are significantly smaller than their normal counterparts. They have severe muscular dystrophy, and the majority die at, or immediately after, birth.
14 Thus, IGF-I plays a critical role in muscle maturation and development. Figure 4 Representative histological sections of injury-sutured hamstring muscles stained by the azan method, and taken 1 week after injection and electroporation of (a) IGF-I DNA injection group, (b) GFP DNA injection group, and (c) injury-sutured group (control); 2 weeks after injection and electroporation of (d) IGF-I DNA injection group, (e) GFP DNA injection group, and (f) injury-sutured group (control); and 4 weeks after injection and electroporation of (g) IGF-I DNA injection group, (h) GFP DNA injection group, and (i) injury-sutured group (control).
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The usefulness of IGF-I protein treatment in skeletal muscle atrophy has been reported in wobbler mice injected daily with recombinant hIGF-I. 15 Injection of a recombinant adeno-associated virus directing overexpression of IGF-I in muscle fibers resulted in an increase in muscle mass and strength in these animals. 16 Direct intramuscular IGF-I DNA injection in pigs resulted in limited expression within 9 mm surrounding the injection site. Maximum amounts of IGF-I protein were observed 3 days after injection, as DNA degradation had occurred in the injected portions. 17 Thus, simple IGF-I DNA injection was restricted to the injected area for a short period of time. Barton-Davis et al 18 showed limited local effects of IGF-I delivery using an adeno-associated virus. The mechanism of the limited local effect is unknown, but it is possible that the muscle extracellular matrix traps all secreted IGF-I. 18 A single 10 mg intramuscular injection of human growth hormone-releasing hormone cDNA into pigs A total of 50 mg of plasmid DNA (IGF-I or GFP) at 1.5 mg/ml in saline was injected into the injury-sutured hamstring muscle model. Electric pulses were applied as described in Figure 1 . (a) Mean number of regenerating myofibers after IGF-I, GFP DNA treatment groups and control group. Control, sham operation of uninjected injury-sutured group. The IGF-I DNA injection group showed the highest number of regenerating myofibers among three groups at a period of 2 weeks after injection and a greater number than that of the control group at a period of 4 weeks after injection. (b) Mean lesser diameter of regenerating myofibers after IGF-I and GFP DNA treatment groups. The IGF-I DNA injection group had a larger diameter of regenerating myofibers than that of the GFP DNA injection group at 4 weeks after injection. Comparisons were made within each time point. Differences between groups were tested by Mann Whitney's U test. All values are expressed as means7s.e.m. 
with electroporation increased the serum concentration of growth hormone and IGF-I. 19 Growth hormone is a strong myogenic factor, and provides systemic effects such as an increase in body weight. Therefore, careful attention to potential systemic side effects must be taken into account before the application of any intramuscular DNA injections in a therapeutic context.
After injury, the muscle undergoes a distinct set of healing phase, consisting of degeneration, inflammation, regeneration, and fibrosis. 20 Suturing the lacerated muscle immediately after injury has been proved to promote better healing of the injured muscle and to prevent the development of deep scar formation in the lacerated muscles compared with that of immobilization of the muscle injury. 21 In this study, we performed IGF-I gene transfer into the muscles of the lower extremity using electroporation to promote repair of muscle injury. There was a greater decrease in the inflammatory cell infiltration in the muscles electroporated with IGF-I than in those electroporated with GFP. 22 A probable interpretation of this observation was that the specific immune response which started around 1 week after the exposition to the antigen is ongoing. The infiltration of lymphocytes into the GFP-electroporated muscles resulted in the appearance of an immune reaction triggered by GFP. Concentrations of serum IGF-I were not affected in our study. Similar results were seen in a study involving liposome delivery of IGF-I DNA. 23 Enhanced regeneration of muscle fiber was observed without systemic changes in serum IGF-I levels. The present study also demonstrated that, whereas the serum level of IGF-I was not increased, IGF-I in the IGF-I DNA-injected muscles did increase.
Alila et al 24 reported that intramuscular injection of IGF-I DNA plasmid using a polyvinylpyrrolidone delivery system resulted in expression that was limited to muscles, and that a sustained level of biologically active hIGF-I was observed. There was limited systemic exposure, lack of immune responses, and overall safety associated with intramusclar injection of hIGF-I cDNA in their study.
A gene delivery system with a polyvinyl base resulted in 10-to 15-fold higher values than DNA in an isotonic saline solution. 25 With electroporation, however, the level of expression was 100-fold higher than without electroporation, making it one of the most efficient among nonviral gene delivery methods. 10 Although we realize the importance of quantitatively measuring the ratio of fibers transduced by the plasmid and their spreading from the injection site, in this study we did not assess the infection rate of IGF DNA by electroporation, because, from the beginning, the infection rate of gene delivery with a non-viral vector was not expected to be high. Further experiments are, IGF-I gene transfer and muscle regeneration T Takahashi et al however, presently under consideration to assess the quantification of the infection ratio. The improvement of muscle regeneration manifested in the injured-injected site was local, limited to the area surrounding the injection site. Electroporation involves intense electric fields applied across cell membranes to create a large transmembrane potential that allows the DNA to enter, probably through transient pores. 2 Although electrostimulation causes some muscle damage, the fibers regenerate rapidly. 26 To our knowledge, there has been no report prior to this study demonstrating the promotion of regeneration in a muscle injury-repair model using IGF-I gene transfer with electroporation. Our results demonstrated that IGF-I gene transfer by electroporation increased the number and diameter of regenerating myofibers and enhanced muscle regeneration following muscle injury. The local muscle concentration of IGF-I in the IGF-I DNA injection group was greater than in the GFP DNA injection group. The effects of the IGF-I production were local, and serum IGF-I levels were not elevated.
It has also been found that IGF-I increases the production of matrix components, such as collagen, and can decrease the expression of matrix-degrading enzymes, such as collagenase, that will contribute to the development of fibrosis. 27 In fact, it has recently been reported that adenoviral gene transfer of IGF-I in injured skeletal muscle can improve muscle healing, but the functional recovery of the injured muscle remains impaired due to the development of scar tissue formation. 20, 28 Gene delivery to muscle using vectors has been shown to induce an inflammatory response because there is immunogenicity in contrast to non-viral methods such as electroporation where immunogenicity is not involved. 29 In this study, at 1 week after injection, all three groups showed moderately positive staining of the matrix of the myofiber. In contrast, IGF-I and control exhibited almost no positive azan staining; however, in the GFP group a little positive staining still remained. The results demonstrated that, at 4 weeks after injection in the IGF-Iinjected group, collagen fibers of the endomysium were found to be slightly increased by azan staining; however, little fibroblastic scar tissue was observed by vimentin staining. IGF-I may induce fibrosis compared to no injection. Further studies are needed to combine the use of antifibrotic agents to reduce fibroblastic tissue formation and improve muscle healing. 20 Exposure to elevated levels of IGF-I has been shown to induce nerve sprouting of adult skeletal muscle. 30 Intramuscular axonal sprouting was reported after 3 weeks of daily systemic hIGF-I protein treatment. 15 Injection of the IGF-I gene into paralyzed adult rat laryngeal muscle using a polyvinyl-based delivery system resulted in a significant increase in the percentage of endplates with nerve contact. 31 The present results showed that CMAP amplitude, which indicates activated muscle and accelerated recovery of nerve conduction, was increased at the IGF-I DNA injection site.
At 4 weeks after injection, full recovery of muscle and nerve functions surrounding the injection was not observed. Since there was a large individual variation, we chose to examine the ratio of CMAP of the injected side to the intact (uninjected) side. Although we recognize the usefulness of the muscle physiology test such as fast-twitch and tetanus strength employed by some authors, 5, 6 in this study we have performed the examination of CMAP because EMG seems to be a better way to examine the muscle and nerve functions together.
This study demonstrated that IGF-I gene transfer with electroporation increased the number and diameter of regenerated myofibers, had no influence on IGF-I serum concentrations, but increased injected muscle IGF-I amounts for a short period of time. Thus, in this muscle-injury model, our method proved to be simple, safe, inexpensive, and useful for regeneration after muscle injury. Future studies are needed to clarify the effects of IGF-I gene delivery with electroporation over a longer period of time, and to improve methods for more efficient gene delivery.
Materials and methods
Construction of IGF-I
Plasmid pCAGGS-IGF-I was constructed by inserting rat IGF-I cDNA (a generous gift from Dr Peter S Rotwein, Oregon Health Sciences University, OR, USA) into the unique EcoRI site between the CAG promoter and a 3 0 -flanking sequence of the rabbit b-globin gene of the pCAGGS expression vector. A pCAGGS-GFP plasmid was constructed by a similar method. Plasmids were grown in E. coli HB 101 cells, extracted by the alkaline lysis method. Purification of plasmid DNA was achieved by chromatography using Qiagen resin according to the manufacture's protocol followed by ethanol precipitation. The DNA was then dissolved in saline. Concentration of endotoxin in DNA plasmids preparation was under 12 pg/ml.
Surgery and gene delivery
A total of 58 mice (BALB/c), 7-8 weeks old, were anesthetized with 0.01-0.02 ml pentobarbital sodium by intraperitoneal injection. The skin of the right posterior thigh was incised to expose the right hamstring muscle, which was cut transversely using a #15 scalpel, and then sutured with a modified Kessler stitch using nylon 7-0 wires. After 1 week, the mice were again anesthetized, and the right hamstring muscles were exposed by reopening the same incision. The injured portion of the muscles was injected with 50 mg of closed circular plasmid DNA (pCAGGS-IGF-I, or control pCAGGS-GFP) solution at 1.5 mg/ml in 0.9% NaCl saline using an insulin syringe with a 27-gauge needle. A pair of parallel steel electrode needles (distance 5 mm) was inserted in parallel orientation with respect to the muscle fibers into the muscle to a depth of 3-5 mm in order to encompass the DNA injection site. Electric pulses with a standard square wave were delivered using an electric pulse generator (CUY 21, BEX Co., Ltd, Tokyo, Japan). Three pulses of 100-V amplitude were administered to each injection site at 1 pulse/s, with each pulse 50 ms in duration. The opposite polarity was then applied in the same manner. 4 The skin was then closed using a 4-0 nylon suture. Sham operations were performed in which the muscle was exposed, cut, and sutured alone (control group).
At different intervals (1, 2, 4 weeks) after the DNA injection, blood samples were taken from the mice and were preserved at À701C. The mice were then killed by IGF-I gene transfer and muscle regeneration T Takahashi et al cervical dislocation. Hamstring muscles were isolated and fixed in 20% formaldehyde for H-E staining or frozen for fluorescent microscopy. For the measurement of IGF-I concentration, muscles were dissected and the weight of each muscle was recorded and freeze-dried. Mice were maintained under specific pathogen-free conditions in the animal facility at Kochi Medical School. All experimental protocols were approved by the Animal Research and Care Committee at Kochi Medical School.
Reporter gene assay
To demonstrate expression of injected genes, dissected muscles were frozen on dry ice, and 8 mm cryostat sections were cut and mounted on glass slides. A confocal laser microscope (Zeiss, Germany) was used to evaluate the expression of GFP in the GFP DNA group.
Staining analysis
Mice were killed at 1, 2, and 4 weeks after IGF-I or GFP DNA injection. Hamstring muscles were fixed in 20% formaldehyde and embedded in paraffin blocks. Transverse sections (4 mm thick) were stained with H-E. To perform quantitative analyses of muscle regeneration in the regions of injury-repair, four or five fields of view were chosen randomly and pictures of microscopic field were taken using Lumina vision 1 (Mitani Corporation, Tokyo, Japan), and the number and diameter of regenerating myofibers were examined with MacScope version 2.59 (Mitani Corporation, Tokyo, Japan). These views were obtained from the injury-repair portions of the hamstrings, as identified by a 7-0 nylon suture marker.
We have determined the number of regenerating myofibers in two or three randomly selected fields of view in which the density of the muscle fibers and the cross-section area of the muscle were not different among three groups within five randomly selected fields. The numbers of regenerating myofibers were counted and the lesser diameter of regenerating myofibers was measured in the transverse sections. 32 The lesser diameter was defined as the maximum diameter across the lesser aspect of the muscle, and then measured blinded randomly 100 myofibers on each group. The numbers and diameters of regenerating myofibers were averaged and compared for each muscle examined. These muscles were embedded, sectioned, and stained with H-E in the same manner as muscles from experimental animals. Sections were also stained using azan and then examined. Immunohistochemical study was performed using a Histofine SAB-PO (multi) kit (Nichirei,Tokyo, Japan). The monoclonal antibodies against vimentin (clone V9; DAKO, Glostrup, Denmark).
Measurement of IGF-I concentration
Blood was obtained at several time intervals after DNA injection. Serum was obtained by centrifugation and stored at À701C. Immediately after the mice were killed, hamstring muscles were dissected bilaterally, weighed, frozen, and stored.
IGF-I serum concentrations were measured by radioimmunoassay (RIA), as described in the manufacturer's instructions (Diagnostic System Laboratories, Webster, TX, USA). The amounts of rat IGF-I in the samples were calculated from a standard curve generated with standard solutions of IGF-I.
For the measurement of the IGF-I concentrations within muscle tissue, freeze-dried samples were weighed and pulverized into a fine powder. Acetic acid of 1 M was then added in a ratio of 1 g of tissue to 40 ml acetic acid. The tissue/acetic acid solution was mixed gently for 2 h. The homogenates were centrifuged at 10,000 Â g for 5 min at 41C, and the supernatants were stored at À701C overnight. The precipitates were then extracted again in the same way and the two supernatants were combined. To further clarify the supernatants, samples were centrifuged at 10,000 Â g for 5 min. The supernatants were next decanted and stored at À701C, and then lyophilized. Lyophilized supernatants were resuspended in assay buffer and assayed directly according to the manufacturer's instructions.
Electromyographic analysis
Four weeks after injection in the IGF-I or GFP-injected group, and 5 weeks after injury-suture in the control group, the mice were anesthetized as previously described, and an incision was made from the posterior iliac to the leg to expose the sciatic nerve. The sciatic nerve was then supramaximally electrostimulated to elicit CMAP of the hamstring muscle. CMAPs were recorded by electromyography (Synax 1100, NEC, Tokyo, Japan). Animals were killed following electromyography. The ratio of the CMAP amplitude between injected and contralateral muscles was evaluated.
Statistical analysis
Statistical analyses were performed using Mann-Whitney's U test: statistical significance was Po 0.05.
